Progenics

From Verify.Wiki
Jump to: navigation, search

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.

QuickUpload1048 20170727120829.jpg
http://www.progenics.com
Type Public
Founded 1988
Headquarters New York, New York
Number of employees 51-200 employees


History

Controversies

Top 5 Recent Tweets

DateAuthorComment
March 31, 2023urotoday#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 3+3=6 GG 1, PALB2 mutations. @HJacene… https://t.co/BJFJ75rbGp
March 30, 2023urotoday#TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal… https://t.co/Mkr6UuP7Nq


Top 5 Recent News Headlines

Top 5 Lifetime Tweets

Top 5 Lifetime News Headlines

Verification history